‘Golden standard’ vaccine to prevent Marek’s disease
Boehringer Ingelheim hails PREVEXXION® RN innovation
A vaccine described as “the new golden standard” in preventing Marek’s disease has been launched in the UK.
Boehringer Ingelheim says PREVEXXION® RN is the first innovation in the Marek category in over 40 years and will give poultry producers cutting-edge technology in terms of disease protection.
Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our PREVEXXION® RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection.
“Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge. PREVEXXION® RN is the new golden standard for Marek’s disease vaccination programs2”.
PREVEXXION® RN range is composed of an innovative serotype-1 construct vaccine with a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.
The vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen and licensed for use in day-old broilers, layers and breeders.
They can also be combined with Vaxxitek HVT+IBD to provide protection against Marek’s disease and infectious burial disease (IBD/Gumboro).
Marek’s disease is a Herpes virus infection of chickens, and rarely turkeys in close association with chickens, seen worldwide.
Morbidity is 10-50% and mortality up to 100%.
The route of infection is usually respiratory and the disease is highly contagious being spread by infective feather-follicle dander, fomites, etc. Infected birds remain viraemic for life.
Full details are available from Boehringer Ingelheim avian specialists.